your point illustrates to a T the wisdom of tony wanting to change his focus to the second part of your quote, as opposed to the first, which was his original intent. in addition to your guess that the window of opportunity won't be very wide, as tony said at the shareholders meeting, to paraphrase: the big money isn't in the classifiers; but, in the selling of the targeted treatments. hence the biofrontra deal. all that has to be done is get over all the potential hurdles to make it happen.
<The window of opportunity for drug classifiers will not be <very wide. Especially as the first generation of targeted <treatments are even now entering the approval process.
News 
Market Data 
Discover 
AI
